Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International https://teapaw.org/t.co/waLoXoDtWZ $AMBS
Amarantus BioScience retweeted
"Behind the Buzz" Show: Amarantus Bioscience Holdings, Inc. (OTC: $AMBS) CEO Gerald Commissiong
#Biotechnology #Diagnostics #Therapeutics #EmeraldOrganicProducts #Hempori #CBD #TodosMedical #ProvistaDx #Alzheimers #MANFTherapeutics #Glaucoma (Sponsored Financial News Content)
Amarantus Releases Letter to Shareholders https://teapaw.org/t.co/YQFiJUWWr5 $AMBS
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori https://teapaw.org/t.co/MHK2jt4BRP $AMBS
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products https://teapaw.org/t.co/pexRqKMEUR $AMBS
Amarantus Provides Recapitalization Update to Shareholders https://teapaw.org/t.co/1mnOv49l9u $AMBS
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation https://teapaw.org/t.co/FoQo3fFwY3 $AMBS
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association https://teapaw.org/t.co/VHJ56IDWjT $AMBS
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference https://teapaw.org/t.co/rOWmTz67TK
$AMBS President & CEO Gerald Commissiong recently presented at the 9th Annual LD Micro Invitational Conference. Listen to a webcast replay here: https://teapaw.org/t.co/GxDMoox6kc
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics https://teapaw.org/t.co/B6DbL1qiEE $AMBS
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan https://teapaw.org/t.co/oybMO8LHY3 $AMBS
MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa https://teapaw.org/t.co/45ON7pvANP $AMBS
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries https://teapaw.org/t.co/a9AqBft93v $AMBS
Amarantus Provides 2019 Roadmap https://teapaw.org/t.co/9p52jr0kBU $AMBS
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0 https://teapaw.org/t.co/i8mq2ct1bc
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma https://teapaw.org/t.co/ZUHrDGlgPj $AMBS
MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology https://teapaw.org/t.co/ax4SKupgqE

